Overview

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Status:
Active, not recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

This is a single-arm phase II clinical trial evaluating the safety and efficacy of the PD-L1 inhibitor durvalumab as first-line therapy in 50 patients with advanced NSCLC and ECOG Performance Status 2 (PS2).

Phase:

Phase 2

Details

Lead Sponsor:

Academic Thoracic Oncology Medical Investigators Consortium
Liza Villaruz, MD

Collaborator:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Durvalumab